Since SAA appears to play a role in the pathogenesis of atherosclerosis (see previous sections), it is possible an approach that inhibits Il-1β could be more widely adapted for preventing atherosclerosis, as well as rheumatic diseases and even in hyperinflammatory states associated with COVID-19 (302). Here, SAA1 is linked to COVID-19.